Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

134
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
134
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

773
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
773
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

157
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
157
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

649
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
649
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.1K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.1K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

2.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stability of optical knots in atmospheric turbulence.

Nature communications·2025
Same author

[PECULIARITIES OF INTERACTION IN THE "PARASITE-HOST" SYSTEM IN HIV-INFECTED PATIENTS WITH TOXOPLASMOSIS: LITERATURE AND CLINICAL CASE REVIEW].

Georgian medical news·2020
Same author

[CLINICAL DIAGNOSTIC VALUE OF OXIDATIVE STRESS MARKERS IN PATIENTS WITH CHRONIC HEART FAILURE. OPPORTUNITIES OF THEIR PHARMACOLOGICAL CORRECTION BY ETOXIDOL].

Georgian medical news·2020
Same author

[CLINICAL CASE: THE SIDE EFFECTS OF STATINS].

Georgian medical news·2020
Same author

[THE SIGNIFICANCE OF THE SYSTEM APPROACH IN THE STUDY OF THE GENERAL ADAPTATION SYNDROME' REACTIONS].

Georgian medical news·2019
Same author

[COMPARATIVE EFFICACY OF DOXYCYCLINE AND GLUCANTIME IN THE TREATMENT OF LEISHMANIASIS IN VITRO].

Georgian medical news·2019

Related Experiment Video

Updated: Dec 14, 2025

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.2K

[PHARMACOGENETIC ASPECTS OF TREATMENT OF PATIENTS WITH CHRONIC HEART FAILURE (REVIEW)].

L Pavlova1, V Kukes2, E Shikh1

  • 12Sechenov First Moscow state medical UNIVERSITY of the Ministry of health of Russia.

Georgian Medical News
|July 17, 2020
PubMed
Summary

Pharmacogenetics influences heart failure treatment by linking genetic variations to drug response and toxicity risk. Understanding these genetic factors can personalize medication choices for better patient outcomes.

More Related Videos

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.7K
Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart
06:07

Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart

Published on: September 2, 2021

2.1K

Related Experiment Videos

Last Updated: Dec 14, 2025

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.2K
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.7K
Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart
06:07

Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart

Published on: September 2, 2021

2.1K

Area of Science:

  • Pharmacology
  • Genetics
  • Cardiology

Background:

  • Heart failure (HF) treatment efficacy and safety can be influenced by individual genetic makeup.
  • Genetic variations may affect the risk of developing heart failure and response to standard therapies.

Purpose of the Study:

  • To review pharmacogenetic findings relevant to chronic heart failure treatment.
  • To explore the impact of genetic polymorphisms on heart failure risk, drug toxicity, and treatment selection.

Main Methods:

  • Review of existing literature on pharmacogenetics in heart failure.
  • Analysis of genetic polymorphisms in drug transporters (e.g., MDR1), drug-metabolizing enzymes (e.g., liver enzymes), and drug targets (e.g., ACE, β1-AP).

Main Results:

  • Polymorphisms in MDR1 gene (encoding P-glycoprotein) are linked to glycoside toxicity.
  • Genetic variations in ACE and liver metabolism affect the efficacy and safety of drugs like torasemide and metoprolol succinate.
  • β1-AP polymorphism influences the clinical use of beta-blockers in heart failure patients.

Conclusions:

  • Pharmacogenetics plays a crucial role in personalizing heart failure pharmacotherapy.
  • Further long-term studies are necessary to fully elucidate the impact of genetic traits on medication efficacy and safety in heart failure.